Eyepoint Pharmaceuticals Stock Price Prediction
| EYPT Stock | USD 17.50 3.44 16.43% |
Oversold Vs Overbought
35
Oversold | Overbought |
Eyepoint Pharmaceuticals stock price prediction is an act of determining the future value of Eyepoint Pharmaceuticals shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Eyepoint Pharmaceuticals' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Eyepoint Pharmaceuticals and does not consider all of the tangible or intangible factors available from Eyepoint Pharmaceuticals' fundamental data. We analyze noise-free headlines and recent hype associated with Eyepoint Pharmaceuticals, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Eyepoint Pharmaceuticals' stock price prediction:EPS Estimate Next Quarter (0.44) | EPS Estimate Current Year (1.94) | EPS Estimate Next Year (2.53) | Wall Street Target Price 43.67 | EPS Estimate Current Quarter (0.49) |
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Eyepoint Pharmaceuticals based on different types of headlines from major news networks to social media. The Eyepoint stock price prediction module provides an analysis of price elasticity to changes in media outlook on Eyepoint Pharmaceuticals over a specific investment horizon. Using Eyepoint Pharmaceuticals hype-based prediction, you can estimate the value of Eyepoint Pharmaceuticals from the perspective of Eyepoint Pharmaceuticals response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Eyepoint Pharmaceuticals using Eyepoint Pharmaceuticals' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Eyepoint using crowd psychology based on the activity and movement of Eyepoint Pharmaceuticals' stock price.
Eyepoint Pharmaceuticals Implied Volatility | 239.82 |
Eyepoint Pharmaceuticals' implied volatility exposes the market's sentiment of Eyepoint Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Eyepoint Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Eyepoint Pharmaceuticals stock will not fluctuate a lot when Eyepoint Pharmaceuticals' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Eyepoint Pharmaceuticals. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Eyepoint Pharmaceuticals to buy its stock at a price that has no basis in reality. In that case, they are not buying Eyepoint because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Eyepoint Pharmaceuticals after-hype prediction price | USD 17.12 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Eyepoint contract
Based on the Rule 16, the options market is currently suggesting that Eyepoint Pharmaceuticals will have an average daily up or down price movement of about 14.99% per day over the life of the 2024-04-19 option contract. With Eyepoint Pharmaceuticals trading at USD 17.5, that is roughly USD 2.62 . If you think that the market is fully incorporating Eyepoint Pharmaceuticals' daily price movement you should consider acquiring Eyepoint Pharmaceuticals options at the current volatility level of 239.82%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Eyepoint |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Eyepoint Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Eyepoint Pharmaceuticals After-Hype Price Prediction Density Analysis
As far as predicting the price of Eyepoint Pharmaceuticals at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Eyepoint Pharmaceuticals or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Eyepoint Pharmaceuticals, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Eyepoint Pharmaceuticals Estimiated After-Hype Price Volatility
In the context of predicting Eyepoint Pharmaceuticals' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Eyepoint Pharmaceuticals' historical news coverage. Eyepoint Pharmaceuticals' after-hype downside and upside margins for the prediction period are 13.25 and 20.99, respectively. We have considered Eyepoint Pharmaceuticals' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Eyepoint Pharmaceuticals is not too volatile at this time. Analysis and calculation of next after-hype price of Eyepoint Pharmaceuticals is based on 3 months time horizon.
Eyepoint Pharmaceuticals Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Eyepoint Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eyepoint Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Eyepoint Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.42 | 3.87 | 0.38 | 0.28 | 10 Events / Month | 5 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
17.50 | 17.12 | 2.17 |
|
Eyepoint Pharmaceuticals Hype Timeline
Eyepoint Pharmaceuticals is currently traded for 17.50. The entity has historical hype elasticity of -0.38, and average elasticity to hype of competition of 0.28. Eyepoint is projected to decline in value after the next headline, with the price expected to drop to 17.12. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -2.17%, whereas the daily expected return is currently at -0.42%. The volatility of related hype on Eyepoint Pharmaceuticals is about 584.89%, with the expected price after the next announcement by competition of 17.78. About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Eyepoint Pharmaceuticals was currently reported as 5.43. The company recorded a loss per share of 1.82. Eyepoint Pharmaceuticals last dividend was issued on the 9th of December 2020. The entity had 1:10 split on the 9th of December 2020. Given the investment horizon of 90 days the next projected press release will be in about 10 days. Check out Eyepoint Pharmaceuticals Basic Forecasting Models to cross-verify your projections.Eyepoint Pharmaceuticals Related Hype Analysis
Having access to credible news sources related to Eyepoint Pharmaceuticals' direct competition is more important than ever and may enhance your ability to predict Eyepoint Pharmaceuticals' future price movements. Getting to know how Eyepoint Pharmaceuticals' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Eyepoint Pharmaceuticals may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ALKS | Alkermes Plc | 0.36 | 9 per month | 0.00 | (0.09) | 2.79 | (4.24) | 21.89 | |
| IRWD | Ironwood Pharmaceuticals | 0.31 | 12 per month | 0.00 | (0.10) | 3.82 | (4.53) | 42.91 | |
| DCPH | Deciphera Pharmaceuticals LLC | (0.12) | 10 per month | 2.52 | (0.02) | 4.84 | (4.32) | 17.94 | |
| EGRX | Eagle Pharmaceuticals | (0.40) | 10 per month | 4.87 | 0.03 | 8.00 | (7.92) | 23.10 | |
| NBIX | Neurocrine Biosciences | 4.08 | 10 per month | 1.56 | (0.04) | 2.61 | (2.36) | 8.06 | |
| DVAX | Dynavax Technologies | (0.26) | 9 per month | 0.00 | (0.27) | 2.49 | (2.90) | 6.78 |
Eyepoint Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Eyepoint price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Eyepoint using various technical indicators. When you analyze Eyepoint charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Eyepoint Pharmaceuticals Predictive Indicators
The successful prediction of Eyepoint Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Eyepoint Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on analysis of Eyepoint Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Eyepoint Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Eyepoint Pharmaceuticals's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 181.36 | 136.67 | 6.39 | 6.07 | PTB Ratio | 1.91 | 1.36 | 3.29 | 3.13 |
Story Coverage note for Eyepoint Pharmaceuticals
The number of cover stories for Eyepoint Pharmaceuticals depends on current market conditions and Eyepoint Pharmaceuticals' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Eyepoint Pharmaceuticals is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Eyepoint Pharmaceuticals' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
View All Premium Stories
Eyepoint Pharmaceuticals Short Properties
Eyepoint Pharmaceuticals' future price predictability will typically decrease when Eyepoint Pharmaceuticals' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Eyepoint Pharmaceuticals often depends not only on the future outlook of the potential Eyepoint Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eyepoint Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.9 M | |
| Cash And Short Term Investments | 331.1 M |
Check out Eyepoint Pharmaceuticals Basic Forecasting Models to cross-verify your projections. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Eyepoint Stock analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Eyepoint Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyepoint Pharmaceuticals. If investors know Eyepoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyepoint Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 1.183 | Quarterly Revenue Growth 0.332 | Return On Assets (0.17) | Return On Equity (0.39) |
The market value of Eyepoint Pharmaceuticals is measured differently than its book value, which is the value of Eyepoint that is recorded on the company's balance sheet. Investors also form their own opinion of Eyepoint Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eyepoint Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyepoint Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eyepoint Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyepoint Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyepoint Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyepoint Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.